Pulished Date August, 2019
ID: 5792
Share on
Share on

Antibody Drug Conjugates Market By Pipeline Analysis (Phase, Mode Of Action [IgG1 Antibodies, HER2 Antibodies], Technology [Seattle Genetics, Immunogen, Immunomedics], Linker), End-user (Research Institutes, Hospitals, Clinics And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecast To 2024

Pulished: August, 2019
ID: 5792
Pages: 175

Antibody Drug Conjugate Market Potential Analysis:

Antibody-drug conjugate (ADC) is a biologically active drug used as targeted therapy in the treatment of cancer that is highly potent drugs of the biopharmaceutical industry. These drugs are chemically complex molecules intended to kill the cancer cells in the body which composed of an antibody that is biologically linked to anticancer drugs. These drugs target multiple pathways and reduce the risk of developing treatment-resistant disorders in the body.

By the mechanism of action, the drugs are segmented into IgG1 antibodies and HER2 antibodies which affect different pathogens like bacteria, fungi, and virus in the body. Antibody-drug conjugates are widely accepting by several small and big pharmaceutical companies that are filling gaps between many oncology product pipelines. These drugs are also used in many other applications like metabolic disorders, cardiovascular, central nervous system, life science research tools, medical imaging, and vaccines.

According to the report, The Global Antibody Drug Conjugates Market was worth USD 11.8 Billion in 2019 and estimated to be growing at a CAGR of 24.74%, to reach USD 35.6 Billion by 2024.

Factors like the rise in cancer incidences, changing lifestyles, high investments by the companies in the pipeline analysis, cancer-killing ability and research development of ADCs, growing biomedical industry, new product innovations and technology advancements are driving the Global Antibody Drug Conjugates Market. However, the high cost of production of ADCs and stringent regulations for the product approval are hindering the growth of the market.

Antibody-Drug Conjugate Industry Segmentation:

The Global Antibody Drug Conjugates Market is segmented on the basis of pipeline analysis, end-user, and region. Based on the pipeline analysis, the market is segmented into phase, mode of action, technology, and linker. The mode of action segment is sub-segmented into IgG1 antibodies and HER2 antibodies. The technology segment is further segmented into Seattle genetics, Immunogen, and Immunomedics. On the basis of End-user, the market is segmented into research institutes, hospitals, clinics and others.

The market has also been geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. North America is dominating the global market due to the presence of large companies in this area and their high investment in the cancer product pipelines. Asia-Pacific is the fastest growing region with a high CAGR owing to the rise in prevalence of cancer and emerging economies like China and India.

Industry Major Players:

  • Seattle Genetics
  • Genentech
  • Takeda Pharmaceuticals
  • Hoffmann-La Roche
  • Bayer Healthcare
  • Agensys, Inc.,
  • Immunogen
  • Novartis
  • Oxford Biotherapeutics
  • Synthon Biopharmaceuticals

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Pipeline Analysis                      

                                5.1.1 Introduction           

                                5.1.2 Phase        

                                5.1.3  Mode of action    

                                                5.1.3.1 IgG1 antibodies

                                                5.1.3.2 HER2 antibodies

                                5.1.4 Technology             

                                                5.1.4.1 Seattle Genetics

                                                5.1.4.2 Immunogen

                                                5.1.4.3 Immunomedics

                                5.1.5 Linker        

                                5.1.6 Y-o-Y Growth Analysis, By Pipeline Analysis              

                                5.1.7 Market Attractiveness Analysis, By Pipeline Analysis            

                                5.1.8 Market Share Analysis, By Pipeline Analysis             

                5.2 End-user                      

                                5.2.1 Introduction           

                                5.2.2 Research institutes              

                                5.2.3 Hospitals  

                                5.2.4 Clinics        

                                5.2.5 Others      

                                5.2.6 Y-o-Y Growth Analysis, By End-user             

                                5.2.7 Market Attractiveness Analysis, By End-user           

                                5.2.8 Market Share Analysis, By End-user             

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Pipeline Analysis

                                                6.1.3.3 By End-user

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Pipeline Analysis

                                                6.1.4.3 By End-user

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Pipeline Analysis

                                                6.1.5.3 By End-user

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Seattle Genetics                       

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Genentech                 

                8.3 Takeda Pharmaceuticals                       

                8.4 F. Hoffmann-La Roche                           

                8.5 Bayer Healthcare                     

                8.6 Agensys, Inc.,                            

                8.7 Immunogen                               

                8.8 Novartis                       

                8.9 Oxford Biotherapeutics                         

                8.10 Synthon Biopharmaceuticals                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms Technology along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Antibody Drug Conjugates  Market By Region, From 2019-2024 ( USD Billion )
  2. Global Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  3. Global Phase Market By Region, From 2019-2024 ( USD Billion )
  4. Global Mode of action Market By Region, From 2019-2024 ( USD Billion )
  5. Global Technology Market By Region, From 2019-2024 ( USD Billion )
  6. Global Linker Market By Region, From 2019-2024 ( USD Billion )
  7. Global Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  8. Global Research institutes Market By Region, From 2019-2024 ( USD Billion )
  9. Global Hospitals Market By Region, From 2019-2024 ( USD Billion )
  10. Global Clinics Market By Region, From 2019-2024 ( USD Billion )
  11. Global Others Market By Region, From 2019-2024 ( USD Billion )
  12. North America Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  13. North America Phase Market By Region, From 2019-2024 ( USD Billion )
  14. North America Mode of action Market By Region, From 2019-2024 ( USD Billion )
  15. North America Technology Market By Region, From 2019-2024 ( USD Billion )
  16. North America Linker Market By Region, From 2019-2024 ( USD Billion )
  17. North America Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  18. North America Research institutes Market By Region, From 2019-2024 ( USD Billion )
  19. North America Hospitals                    Market By Region, From 2019-2024 ( USD Billion )
  20. North America Clinics Market By Region, From 2019-2024 ( USD Billion )
  21. North America Others Market By Region, From 2019-2024 ( USD Billion )
  22. United States Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  23. United States Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  24. Canada Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  25. Canada Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  26. Europe Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  27. Europe Phase Market By Region, From 2019-2024 ( USD Billion )
  28. Europe Mode of action Market By Region, From 2019-2024 ( USD Billion )
  29. Europe Technology Market By Region, From 2019-2024 ( USD Billion )
  30. Europe Linker Market By Region, From 2019-2024 ( USD Billion )
  31. Europe Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  32. Europe Research institutes Market By Region, From 2019-2024 ( USD Billion )
  33. Europe Hospitals Market By Region, From 2019-2024 ( USD Billion )
  34. Europe Clinics Market By Region, From 2019-2024 ( USD Billion )
  35. Europe Others Market By Region, From 2019-2024 ( USD Billion )
  36. U.K. Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  37. U.K. Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  38. Germany Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  39. Germany Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  40. France Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  41. France Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  42. Italy Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  43. Italy Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  44. Spain Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  45. Spain Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  46. Asia Pacific Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  47. Asia Pacific Phase Market By Region, From 2019-2024 ( USD Billion )
  48. Asia Pacific Mode of action Market By Region, From 2019-2024 ( USD Billion )
  49. Asia Pacific Technology Market By Region, From 2019-2024 ( USD Billion )
  50. Asia Pacific Linker Market By Region, From 2019-2024 ( USD Billion )
  51. Asia Pacific Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  52. Asia Pacific Research institutes Market By Region, From 2019-2024 ( USD Billion )
  53. Asia Pacific Hospitals Market By Region, From 2019-2024 ( USD Billion )
  54. Asia Pacific Clinics Market By Region, From 2019-2024 ( USD Billion )
  55. Asia Pacific Others Market By Region, From 2019-2024 ( USD Billion )
  56. Japan Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  57. Japan Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  58. China Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  59. China Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  60. India Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  61. India Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  62. Australia Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  63. Australia Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  64. South Korea Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  65. South Korea Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  66. Latin America Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  67. Latin America Phase Market By Region, From 2019-2024 ( USD Billion )
  68. Latin America Mode of action Market By Region, From 2019-2024 ( USD Billion )
  69. Latin America Technology Market By Region, From 2019-2024 ( USD Billion )
  70. Latin America Linker Market By Region, From 2019-2024 ( USD Billion )
  71. Latin America Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  72. Latin America Research institutes Market By Region, From 2019-2024 ( USD Billion )
  73. Latin America Hospitals Market By Region, From 2019-2024 ( USD Billion )
  74. Latin America Clinics Market By Region, From 2019-2024 ( USD Billion )
  75. Latin America Others Market By Region, From 2019-2024 ( USD Billion )
  76. Brazil Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  77. Brazil Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  78. Argentina Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  79. Argentina Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  80. Mexico Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  81. Mexico Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  82. Rest of Latin America Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  83. Rest of Latin America Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  84. Middle East and Africa Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  85. Middle East and Africa Phase Market By Region, From 2019-2024 ( USD Billion )
  86. Middle East and Africa Mode of action Market By Region, From 2019-2024 ( USD Billion )
  87. Middle East and Africa Technology Market By Region, From 2019-2024 ( USD Billion )
  88. Middle East and Africa Linker Market By Region, From 2019-2024 ( USD Billion )
  89. Middle East and Africa Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  90. Middle East and Africa Research institutes Market By Region, From 2019-2024 ( USD Billion )
  91. Middle East and Africa Hospitals Market By Region, From 2019-2024 ( USD Billion )
  92. Middle East and Africa Clinics Market By Region, From 2019-2024 ( USD Billion )
  93. Middle East and Africa Others Market By Region, From 2019-2024 ( USD Billion )
  94. Middle East Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  95. Middle East Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )
  96. Africa Antibody Drug Conjugates  Market By Pipeline Analysis , From 2019-2024 ( USD Billion )
  97. Africa Antibody Drug Conjugates  Market By End-user , From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample